Ligand Pharma (LGND) Target Up to $91 at Summer Street

Summer Street analyst Carol Werther reiterated a Buy rating on Ligand Pharma (NASDAQ: LGND) and raised her price target from $78 to $91 after updating their model to include 4Q13 EPS and 2014 guidance.

Providing a list of various late stage programs they find most important, with Kyprolis the most binary and Merck's BACE inhibitor data a promising risk/reward, the analyst highlights: 1) Duavee US launch, 2) Fablyn launch, 3) Kyprolis ASPIRE/FOCUS data, 4) SPPI’s filing of Melphalan, 5) Merck’s BACE inhibitor data, 6) Noxafil IV approval, 7) Lundbeck’s CE-carbamezipine approval, 8) Hospira’s undisclosed launch

For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.

Shares of Ligand Pharma closed at $73.20 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Bristol-Myers Squibb Co. (BMY) PT Lowered to $64 at Truist Securities
• First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen
• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban